American Journal of Kidney Diseases
Volume 50, Issue 6 , Pages 989-1000 , December 2007

Efficacy of Intravenous Methoxy Polyethylene Glycol-Epoetin Beta Administered Every 2 Weeks Compared With Epoetin Administered 3 Times Weekly in Patients Treated by Hemodialysis or Peritoneal Dialysis: A Randomized Trial

  • Marian Klinger, MD, PhD

      Affiliations

    • Department of Nephrology and Transplantation Medicine, Medical University, Wroclaw, Poland
    • Corresponding Author InformationAddress correspondence to Marian Klinger, MD, Department of Nephrology and Transplantation Medicine, Medical University, 57/59 Traugutta, 50-417 Wroclaw, Poland.
    • ,
  • Manual Arias, PhD

      Affiliations

    • Servicio de Nefrologia, Hospital Marques de Valdecilla, Santander, Spain
    • ,
  • Vassilis Vargemezis, MD

      Affiliations

    • Department of Nephrology, University Hospital, Alexandroupolis, Greece
    • ,
  • Anatole Besarab, MD

      Affiliations

    • Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI
    • ,
  • Wladyslaw Sulowicz, MD, PhD

      Affiliations

    • Collegium Medicum, Jagiellonian University Department of Nephrology, Cracow, Poland
    • ,
  • Trevor Gerntholtz, FCP (SA)

      Affiliations

    • Department of Nephrology, Chris Hani Baragwanath Hospital, Dumisami Mzamane African Institute of Kidney Diseases, Johannesburg, South Africa
    • ,
  • Kazimierz Ciechanowski, MD, PhD

      Affiliations

    • Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Szczecin, Poland
    • ,
  • Frank C. Dougherty, MD

      Affiliations

    • F. Hoffmann-La Roche Ltd, Basel, Switzerland.
    • ,
  • Ulrich Beyer, PhD

      Affiliations

    • F. Hoffmann-La Roche Ltd, Basel, Switzerland.
    • ,
  • AMICUS Study Investigators

Received 27 February 2007 ,Accepted 30 August 2007.

References 

  1. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–1191
  2. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991;50:702–712
  3. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392–2395
  4. Locatelli F, Aljama P, Bárány P, et al. European Best Practice Guidelines Working Group Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl 2):ii1–ii47
  5. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(suppl 3):S11–S145
  6. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant. 2004;19:898–903
  7. Disney A, De Jersey P, Kirkland G, et al. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, open-label, Australian study. Nephrology. 2007;12:95–101
  8. Grzeszczak W, Sulowicz W, Rutkowski B, et al. European Collaborative Group The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin β in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant. 2005;20:936–944
  9. Ling B, Walczyk M, Agarwal A, Carrol W, Lui W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005;63:327–334
  10. Provenzano R, Bhaduri S, Singh AK PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clin Nephrol. 2005;2:113–123
  11. Agarwal AK, Silver MR, Reed JE, et al. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med. 2006;260:577–585
  12. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int. 2003;64:1514–1521
  13. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41:111–124
  14. Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis. 2005;46:481–488
  15. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337–1343
  16. Macdougall IC, Wilson P, Roche A. Impact of haemoglobin variability in haemodialysis patients receiving erythropoiesis-stimulating agents for the management of renal anaemia. J Am Soc Nephrol. 2005;16:899A;(abstr PUB541)
  17. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001;12:2753–2758
  18. Roderick P, Davies R, Jones C, Feest T, Smith S, Farrington K. Simulation model of renal replacement therapy: predicting future demand in England. Nephrol Dial Transplant. 2004;19:692–701
  19. US Renal Data System. USRDS 2005 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005;
  20. Macdougall IC. CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4:436–440
  21. Dougherty FC, Reigner B, Jordan P, Pannier A. Continuous erythropoiesis receptor activator (CERA) provides dose-dependent erythropoietic activity with a prolonged half-life in healthy volunteers. Ann Oncol. 2004;15(suppl 3):iii157A;(abstr 592P)
  22. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:1211–1215
  23. Besarab A, Salifu MO, Lunde NM, et al. BA16285 Study Group Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clin Ther. 2007;29:626–639
  24. Locatelli F, Villa G, de Francisco ALM, et al. BA16286 Study Group Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin. 2007;23:969–979
  25. Provenzano R, Besarab A, Macdougall IC, et al. BA16528 Study Group The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol. 2007;67:306–317
  26. de Francisco AL, Sulowicz W, Klinger M, et al. BA16260 Study Investigators Continuous erythropoietin receptor activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract. 2006;60:1687–1696
  27. Levin NW, Fishbane S, Valdés Cañeno F, et al. MAXIMA study investigators Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007;370:1415–1421
  28. Sulowicz W, Locatelli F, Ryckelynck J-P, et al. Once-monthly subcutaneous C.E.R.A. maintains stable Hb control in patients with chronic kidney disease on dialysis directly converted from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2:637–646
  29. Canaud B, Braun J, Locatelli F, et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis. Nephrol Dial Transplant. 2006;21(suppl 4):iv157A;(abstr SP425)
  30. Coyne DW, Ling BN, Toto R, McDermott-Vitak AD, Trotman ML, Jackson L. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant-human erythropoietin (r-HuEPO). J Am Soc Nephrol. 2000;11:263A;(abstr A1380)
  31. Suranyi MG, Lindberg JS, Navarro J, Elias C, Brenner RM, Walker R. Treatment of anaemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol. 2003;23:106–111
  32. Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol. 2004;24:453–460
  33. Amico P, Dickenmann M, Steiger J, Saldutto B. Extended dosing with darbepoetin alfa in patients with chronic kidney disease on hemodialysis. Nephrol Dial Transplant. 2006;21(suppl 4):iv154A;(abstr SP417)
  34. Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C. Aranesp® (darbepoetin alfa) administered once every 2 weeks (Q2W) maintains recommended haemoglobin (Hb) in chronic kidney disease (CKD) patients on haemodialysis switched from weekly (QW) dosing. Nephrol Dial Transplant. 2006;21(suppl 4):iv148–iv149(abstr SP401)
  35. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7:763–773
  36. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA. 1990;263:825–830
  37. El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005;365:331–340
  38. Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. (continuous erythropoietin receptor activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis. J Am Soc Nephrol. 2006;17:619A;(abstr SA-PO208)

 Trial registration: www.clinicaltrials.gov; study number: NCT00077597.

 Originally published online as doi:10.1053/j.ajkd.2007.08.013 on October 30, 2007.

PII: S0272-6386(07)01197-3

doi: 10.1053/j.ajkd.2007.08.013

American Journal of Kidney Diseases
Volume 50, Issue 6 , Pages 989-1000 , December 2007

Article Tools

* Image Usage & Resolution